Combination of Doxorubicin with Gemcitabine-Incorporated GQuadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Doxorubicin (DOX) is one of the most effective anticancer agents used for the treatment of multiple cancers; however, its use is limited by its short half-life and adverse drug reactions, especially cardiotoxicity. In this study, we found that the conjugate of DOX with APTA12 (Gemcitabine incorporated G-quadruplex aptamer) was significantly more cancer selective and cytotoxic than DOX. The conjugate had an affinity for nucleolin, with higher uptake and retention into the cancer cells than those of DOX. Further, it was localized to the nucleus, which is the target site of DOX. Owing to its mechanism of action, DOX has the ability to intercalate into the nucleotides thus making it a suitable drug to form a conjugate with cancer selective aptamers such as APTA12. The conjugation can lead to selectively accumulate in the cancer cells thus decreasing its potential nonspecific as well as cardiotoxic side effects. The aim of this study was to prepare a conjugate of DOX with APTA12 and assess the chemotherapeutic properties of the conjugate specific to cancer cells. The DOX-APTA12 conjugate was prepared by incubation and its cytotoxicity in MCF-10A (non-cancerous mammary cells) and MDA-MB-231 (breast cancer cells) was assessed. The results indicate that DOX-APTA12 conjugate is a potential option for chemotherapy especially for nucleolin expressing breast cancer with reduced doxorubicin associated side effects.
Abstract
Doxorubicin (DOX) is one of the most effective anticancer agents used for the treatment of multiple cancers; however, its use is limited by its short half-life and adverse drug reactions, especially cardiotoxicity. In this study, we found that the conjugate of DOX with APTA12 (Gemcitabine incorporated G-quadruplex aptamer) was significantly more cancer selective and cytotoxic than DOX. The conjugate had an affinity for nucleolin, with higher uptake and retention into the cancer cells than those of DOX. Further, it was localized to the nucleus, which is the target site of DOX. Owing to its mechanism of action, DOX has the ability to intercalate into the nucleotides thus making it a suitable drug to form a conjugate with cancer selective aptamers such as APTA12. The conjugation can lead to selectively accumulate in the cancer cells thus decreasing its potential nonspecific as well as cardiotoxic side effects. The aim of this study was to prepare a conjugate of DOX with APTA12 and assess the chemotherapeutic properties of the conjugate specific to cancer cells. The DOX-APTA12 conjugate was prepared by incubation and its cytotoxicity in MCF-10A (non-cancerous mammary cells) and MDA-MB-231 (breast cancer cells) was assessed. The results indicate that DOX-APTA12 conjugate is a potential option for chemotherapy especially for nucleolin expressing breast cancer with reduced doxorubicin associated side effects.
참고문헌 (30)
- Chaires JB, "Preferential binding of daunomycin to 5’TACG and 5’TAGC sequences revealed by footprinting titration experiments", Biochemistry, 29, pp.6145~6153 (1990)
- Singal PK, "Combination therapy with probucol prevents adriamycininduced cardiomyopathy", J. Mol. Cell. Cardiol, 27, pp.1055~1063 (1995)
- (NHL-14), "Eur. J. Cancer", 2016, 112~121
- Bates PJ, "Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer", Exp. Mol. Pathol, 86, pp.151~164 (2009)
- Gold L, "Oligonucleotides as research, diagnostic, and therapeutic agents", J. Biol. Chem, 270, pp.13581~13584 (1995)
- Bates PJ, "G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent : Uses and mechanisms", Biochim. Biophys. Acta Gen. Subj, 1861, pp.1414~1428 (2017)
- Rosenberg JE, "A phase II trial of AS1411(a novel nucleolin-targeted DNA aptamer)in metastatic renal cell carcinoma", Invest. New Drugs, 32, pp.178~187 (2014)
- Park JY, "Gemcitabine-incorporated G-Quadruplex aptamer for targeted drug delivery into pancreas cancer", Mol. Ther. Nucleic Acids, 12, pp.543~553 (2018)
- Reyes-Reyes EM, "A new paradigm for aptamer therapeutic AS1411 action : uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism", Cancer Res, 70, pp.817~829 (2010)
- Fonseca NA, "Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination", Biomaterials, 69, pp.76~88 (2015)
- Qiu W, "Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer", APMIS, 121, pp.919~925 (2013)
- Berger CM, "The roles of nucleolin subcellular localization in cancer", Biochimie, 113, pp.78~85 (2015)
- Rivera E, "Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer", J. Clin. Oncol, 21, pp.3249~3254 (2003)
- Ueno H, "Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?", Br, J. Cancer, 97, pp.145~151 (2007)
- Huang P, "Action of 2’, 2’-difluorodeoxycytidine on DNA synthesis", Cancer Res, 51, pp.6110~6117 (1991)
- Maréchal R, "Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma", Clin. Cancer Res, 15, pp.2913~2919 (2009)
- Mackey JR, "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines", Cancer Res, 58, pp.4349~4357 (1998)
- Vrignaud S, "Strategies for the nanoencapsulation of hydrophilic molecules in polymerbased nanoparticles", Biomaterials, 32, pp.8593~8604 (2011)
- Manoj Amrutkar, "Pancreatic Cancer Chemoresistance to Gemcitabine", Cancers, 9(12), pp.157~ (2017), MDPI AG[DOI]
- Li L, "Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells", Int. J. Nanomedicine, 9, pp.1083~1096 (2014)
- Zhou W, "Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells", J. Drug Target, 22, pp.57~66 (2014)
- Ray P, "Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells", Nucleic Acid Ther, 22, pp.295~305 (2012)
- Shahidi-Hamedani N, "Targeted gene delivery with noncovalent electrostatic conjugates of sgc-8c aptamer and polyethylenimine", J. Gene. Med, 15, pp.261~269 (2013)
- Bagalkot V, "An aptamer–doxorubicin physical conjugate as a novel targeted drug-delivery platform", Angew. Chem. Int. Ed. Engl, 45, pp.8149~8152 (2006)
- Vogus DR, "A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer", J. Control. Release, 267, pp.191~202 (2017)
- Vogus DR, "Schedule dependent synergy of gemcitabine and doxorubicin : Improvement of in vitro efficacy and lack of in vitro-in vivo correlation", Bioeng. Trans. Med, 3, pp.49~57 (2018)
- Ling Y-H, "Cell cycle-dependent cytotoxicity, G2", M phase arrest, and disruption of p34cdc2, Mol. Pharmacol, pp.1996, 49[DOI]
- Matthews DJ, "Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo", Cell Cycle, 6, pp.104~110 (2007)
- Xu X, "Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides", J. Biol. Chem, 276, pp.43221~43230 (2001)
- Hovanessian AG, "Surface expressed nucleolin is constantly induced in tumor cells to mediate calciumdependent ligand internalization", PLoS One, 5, pp.e15787~ (2010)